PMID- 26946415
OWN - NLM
STAT- MEDLINE
DCOM- 20180406
LR  - 20190318
IS  - 1522-9645 (Electronic)
IS  - 0195-668X (Linking)
VI  - 37
IP  - 45
DP  - 2016 Dec 1
TI  - Anticoagulation in coronary intervention.
PG  - 3376-3385
LID - 10.1093/eurheartj/ehw061 [doi]
AB  - Percutaneous coronary intervention (PCI) induces thrombin generation and is 
      associated with the risk of acute, subacute, or long-term ischaemic events. 
      Therefore, intravenous anticoagulation is recommended to minimize thrombotic 
      complications. The intensity and duration of anticoagulation needed are dependent 
      on the clinical presentation (elective PCI for stable coronary artery disease, 
      PCI for non-ST elevation acute coronary syndromes, or primary PCI for ST-segment 
      elevation myocardial infarction) and procedural features. As both ischaemic and 
      periprocedural bleeding complications are associated with acute and long-term 
      mortality, the optimal level of anticoagulation and the best agents are a matter 
      of debate. Despite a number of limitations and the lack of large randomized 
      clinical trials, unfractionated heparin (UFH) is still been used in the majority 
      of interventions. Intravenous enoxaparin, a low-molecular-weight heparin, leads 
      to a more predictable level of anticoagulation and has been compared with UFH in 
      patients with elective PCI and primary PCI with favourable results. The direct 
      thrombin inhibitor bivalirudin has been studied in numerous trials and 
      consistently shown to reduce bleeding complications when compared with UFH with 
      or without glycoprotein IIb/IIIa inhibitors. This review will summarize the 
      current status of anticoagulation for PCI and the results of most recent trials 
      and give recommendations for different clinical scenarios.
CI  - Published on behalf of the European Society of Cardiology. All rights reserved. (c) 
      The Author 2016. For permissions please email: journals.permissions@oup.com.
FAU - Zeymer, Uwe
AU  - Zeymer U
AD  - Klinikum Ludwigshafen und Institut fur Herzinfarktforschung Ludwigshafen, 
      Bremserstrasse 79, 67063 Ludwigshafen, Germany zeymeru@klilu.de.
FAU - Rao, Sunil V
AU  - Rao SV
AD  - The Duke Clinical Research Institute, Durham, NC, USA.
FAU - Montalescot, Gilles
AU  - Montalescot G
AD  - ACTION Study Group, Institut de Cardiologie, Centre Hospitalier Universitaire 
      Pitie-Salpetriere, Paris, France.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20160305
PL  - England
TA  - Eur Heart J
JT  - European heart journal
JID - 8006263
RN  - 0 (Anticoagulants)
RN  - 0 (Antithrombins)
RN  - 0 (Hirudins)
RN  - 0 (Peptide Fragments)
RN  - 0 (Platelet Glycoprotein GPIIb-IIIa Complex)
RN  - 0 (Recombinant Proteins)
RN  - 9005-49-6 (Heparin)
SB  - IM
MH  - Angioplasty, Balloon, Coronary
MH  - Anticoagulants/*therapeutic use
MH  - Antithrombins
MH  - Coronary Disease
MH  - Heparin
MH  - Hirudins
MH  - Humans
MH  - Peptide Fragments
MH  - Platelet Glycoprotein GPIIb-IIIa Complex
MH  - Recombinant Proteins
OTO - NOTNLM
OT  - *Anticoagulation
OT  - *Percutaneous coronary intervention
OT  - *Thrombin inhibition
EDAT- 2016/03/08 06:00
MHDA- 2018/04/07 06:00
CRDT- 2016/03/07 06:00
PHST- 2015/07/04 00:00 [received]
PHST- 2016/01/28 00:00 [revised]
PHST- 2016/01/28 00:00 [accepted]
PHST- 2016/03/08 06:00 [pubmed]
PHST- 2018/04/07 06:00 [medline]
PHST- 2016/03/07 06:00 [entrez]
AID - ehw061 [pii]
AID - 10.1093/eurheartj/ehw061 [doi]
PST - ppublish
SO  - Eur Heart J. 2016 Dec 1;37(45):3376-3385. doi: 10.1093/eurheartj/ehw061. Epub 
      2016 Mar 5.